MARKET

NVS

NVS

Novartis
NYSE
103.25
-0.65
-0.63%
After Hours: 103.24 -0.01 -0.01% 19:25 02/26 EST
OPEN
104.58
PREV CLOSE
103.90
HIGH
104.65
LOW
103.18
VOLUME
2.06M
TURNOVER
0
52 WEEK HIGH
108.78
52 WEEK LOW
75.68
MARKET CAP
211.05B
P/E (TTM)
14.55
1D
5D
1M
3M
1Y
5Y
Merck Said Along With AstraZeneca, Filed A Patent Infringement Lawsuit In The U.S. District Court For The District Of New Jersey Against Novartis Sandoz Unit
Benzinga · 9h ago
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
Roche and Novartis AG are co-developing and co-promoting Xolair. The FDA recently approved the expanded use of Xol air in children and adults with food allergies. Roche announced data from a Phase 3 study of the drug in patients allergic to peanuts and at least two other foods.
Benzinga · 15h ago
Weekly Report: what happened at NVS last week (0219-0223)?
Weekly Report · 21h ago
Radiopharmaceutical market expected to reach ~$14B by 2032
The international market for radiopharmaceuticals is expected to reach $13.67B by 2032. Radiopharma market expected to grow at a compound annual growth rate of 10.2% from 2023. The rising prevalence of cancer and an aging population are among the tailwinds for market growth.
Seeking Alpha · 1d ago
BMO Capital Initiates Coverage On Novartis with Market Perform Rating, Announces Price Target of $114
Benzinga · 3d ago
First Week of NVS March 15th Options Trading
NASDAQ · 4d ago
Looking Into Novartis's Recent Short Interest
Novartis's short percent of float has fallen 9.09% since its last report. The company has 3.89 million shares sold short, which is 0.2% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 4d ago
Emergent surges 66% as it brings in Bausch + Lomb vet Papa as CEO
Emergent surges 66% as it brings in Bausch + Lomb vet Papa as CEO. Joseph Papa has been appointed CEO of Emergent Biosolutions. He was previously CEO at Perrigo and Novartis. Emergent's stock is up 66% in Wednesday afternoon trading.
Seeking Alpha · 5d ago
More
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers Novartis AG (ADR) stock information, including NYSE: NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.